• References (3)
  • Citations (5)
Cite
References3
Published on May 1, 2015in Scientific Reports 4.12
Toru Suzuki5
Estimated H-index: 5
,
Maki Asami3
Estimated H-index: 3
,
Anthony C.F. Perry32
Estimated H-index: 32
Mammalian genomes can be edited by injecting pronuclear embryos with Cas9 cRNA and guide RNA (gRNA) but it is unknown whether editing can also occur during the onset of embryonic development, prior to pronuclear embryogenesis. We here report Cas9-mediated editing during sperm-induced meiotic exit and the initiation of development. Injection of unfertilized, mouse metaphase II (mII) oocytes with Cas9 cRNA, gRNA and sperm enabled efficient editing of transgenic and native alleles. Pre-loading oocy...
22 Citations Source Cite
Published on Jun 1, 2017in Molecular Genetics and Genomics 2.73
Lichun Tang1
Estimated H-index: 1
(Protein Sciences),
Yanting Zeng1
Estimated H-index: 1
(Guangzhou Medical University)
+ 8 AuthorsXiaowei Li1
Estimated H-index: 1
(Nanjing University)
Previous works using human tripronuclear zygotes suggested that the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system could be a tool in correcting disease-causing mutations. However, whether this system was applicable in normal human (dual pronuclear, 2PN) zygotes was unclear. Here we demonstrate that CRISPR/Cas9 is also effective as a gene-editing tool in human 2PN zygotes. By injection of Cas9 protein complexed with the appropriate sgRNAs and homology donors into o...
74 Citations Source Cite
Published on Aug 1, 2017in Nature 41.58
Hong Ma27
Estimated H-index: 27
(Oregon National Primate Research Center),
Nuria Marti-Gutierrez1
Estimated H-index: 1
(Oregon Health & Science University)
+ 28 AuthorsRiffat Ahmed10
Estimated H-index: 10
(Oregon Health & Science University)
Genome editing could be applied to correct disease-causing mutations in human embryos, but concerns about efficacy and safety are paramount. Shoukhrat Mitalipov and colleagues use CRISPRCas9 to correct a heritable cardiomyopathy mutation in human embryos. By optimizing the experimental conditions, the authors show very reduced mosaicism, and report that for this heterozygous mutation, CRISPRCas9-induced breaks seem to be preferentially repaired using the wild-type allele as a template in human e...
238 Citations Source Cite
  • References (3)
  • Citations (5)
Cite
Cited By5
Published on Jan 1, 2019in Molecular Neurobiology 5.08
Sudhanshu P. Raikwar13
Estimated H-index: 13
(University of Missouri),
Ramasamy Thangavel5
Estimated H-index: 5
(University of Missouri)
+ 6 AuthorsAsgar Zaheer29
Estimated H-index: 29
(University of Missouri)
Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder that leads to severe cognitive impairment in elderly patients. Chronic neuroinflammation plays an important role in the AD pathogenesis. Glia maturation factor (GMF), a proinflammatory molecule discovered in our laboratory, is significantly upregulated in various regions of AD brains. We have previously reported that GMF is predominantly expressed in the reactive glial cells surrounding the amyloid plaques (APs) in...
4 Citations Source Cite
Published on Oct 1, 2018in Hearing Research 2.82
Jenna Devare (Kresge Hearing Research Institute), Samuel P. Gubbels11
Estimated H-index: 11
(University of Colorado Denver),
Yehoash Raphael50
Estimated H-index: 50
(Kresge Hearing Research Institute)
Abstract Drug delivery to the inner ear is an ideal method to treat a wide variety of otologic conditions. A broad range of potential applications is just beginning to be explored. New approaches combine principles of inner ear pharmacokinetics with emerging technologies of drug delivery including novel delivery systems, drug-device combinations, and new categories of drugs. Strategies include cell-specific targeting, manipulation of gene expression, local activation following systemic delivery,...
Source Cite
Published on Jan 1, 2019in Progress in Retinal and Eye Research 11.65
Jia Hui Lee3
Estimated H-index: 3
,
Jiang-Hui Wang4
Estimated H-index: 4
(University of Melbourne)
+ 4 AuthorsGuei-Sheung Liu18
Estimated H-index: 18
Abstract Many clinical trials using gene therapy have shown significant therapeutic benefits and exceptional safety records. Increasing evidence is verifying the long sought-after promise that gene therapy will genetically ‘cure’ some severely disabling diseases. In particular, the first gene therapy bioproduct for RPE65 -associated Leber's congenital amaurosis, which was approved by the US Food and Drug Administration in 2017, has provided tremendous encouragement to the field of gene therapy. ...
4 Citations Source Cite